Community acquired pneumonia in children: Treatment of complicated cases and risk patients. Consensus statement by the Spanish Society of Paediatric Infectious Diseases (SEIP) and the Spanish Society of Paediatric Chest Diseases (SENP)

Moreno-Pérez, David; Martín, Arturo Sousa; García, Alfredo Tagarro; Montaner, Amparo Escribano; Mulet, J. Figuerola; Garcı́a, Javier; Moreno‐Galdó, Antonio; Lliria, C. Rodrigo Gonzalo de; Lozano, J. Saavedra

doi:10.1016/j.anpede.2015.08.002

Cited by 9 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 Because of the stable prevalence of S. aureus CAP, recent updates to guidelines recommend maintaining aminopenicillins as first-line treatment for most cases of CAP, since they remain highly active against S. pyogenes and S. pneumoniae . 8,9,18…”

Section: Discussionmentioning

confidence: 99%

Staphylococcus aureus Community-acquired Pneumonia in Children After 13-Valent Pneumococcal Vaccination (2008–2018): Epidemiology, Clinical Characteristics and Outcomes

Aguilera‐Alonso

Nieto²,

Montojo

et al. 2022

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Background:The epidemiology of community-acquired pneumonia (CAP) has changed, influenced by sociosanitary conditions and vaccination status. We aimed to analyze the recent epidemiology of bacterial CAP in hospitalized children in a setting with high pneumococcal vaccination coverage and to describe the clinical characteristics of pediatric Staphylococcus aureus CAP. Methods: Children <17 years old hospitalized from 2008 to 2018 with bacterial CAP in 5 tertiary hospitals in Spain were included. Cases with pneumococcal CAP were randomly selected as comparative group following a case-control ratio of 2:1 with S. aureus CAP. Results: A total of 313 bacterial CAP were diagnosed: Streptococcus pneumoniae CAP (n = 236, 75.4%), Streptococcus pyogenes CAP (n = 43, 13.7%) and S. aureus CAP (n = 34, 10.9%). Throughout the study period, the prevalence of S. pyogenes increased (annual percentage change: +16.1% [95% CI: 1.7-32.4], P = 0.031), S. pneumoniae decreased (annual percentage change: -4.4% [95 CI: -8.8 to 0.2], P = 0.057) and S. aureus remained stable. Nine isolates of S. aureus (26.5%) were methicillin-resistant. Seventeen cases (50%) with S. aureus CAP had some pulmonary complication and 21 (61.7%) required intensive care. S. pneumoniae CAP showed a trend toward higher prevalence of pulmonary complications compared with S. aureus CAP (69.1% vs. 50.0%, P = 0.060), including higher frequency of pulmonary necrosis (32.4% vs. 5.9%, P = 0.003). Conclusions:The incidence of S. aureus CAP in children remained stable, whereas the prevalence of pneumococcal CAP decreased and S. pyogenes CAP increased. Patients with S. aureus presented a high frequency of severe outcomes, but a lower risk of pulmonary complications than patients with S. pneumoniae.

show abstract

Section: Discussionmentioning

confidence: 99%

Staphylococcus aureus Community-acquired Pneumonia in Children After 13-Valent Pneumococcal Vaccination (2008–2018): Epidemiology, Clinical Characteristics and Outcomes

Aguilera‐Alonso

Nieto²,

Montojo

et al. 2022

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

show abstract

“…Рекомендуется в максимально ранние сроки назначить этиотропную противовирусную терапию ингибиторами нейраминидазы осельтамивиром с возраста 1 года на 5 дней или занамивиром детям с ВП тяжелого течения при подозрении на грипп А и В во время эпидемиче-КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ CLINICAL RECOMMENDATIONS ского подъема заболеваемости гриппом с целью максимально эффективной терапии [2,33,94] (УУР -С; УДД -5). Поскольку максимально эффективна именно ранняя противовирусная терапия (в первые 24-48 ч болезни), не следует откладывать лечение до получения результатов исследований на грипп.…”

Section: противовирусная терапияunclassified

Modern approaches at the management of children with community-acquired pneumonia

et al. 2023

View full text Add to dashboard Cite

Experts of The Union of Pediatricians of Russia have developed current clinical guidelines for management of children with community-acquired pneumonia, which were approved by the Scientific and Practice Council of Ministry of Public Health of the Russian Federation in January 2022. Particular attention is paid to the etiological structure, modern classification, diagnostic tests and flagship approaches to antibacterial therapy of community-acquired pneumonia in children based on the principles of evidentiary medicine.

show abstract

“…The survey was completed by 124 pediatricians or pediatric surgeons experts in intensive care (37%), respiratory diseases (27%), infectious diseases (26%) and pediatric surgery (10%) working all over Spain, notably from Madrid (30%) and Barcelona (11%), mostly attending in hospitals equipped to care for children affected with empyema (83%), treating a median of 10 patients annually (interquartile range: 5–20) per center. Most centers (54%) follow guidelines published in Spain and 38% have indeed their own guidelines; 17% centers do not follow any particular guideline.…”

Section: To the Editormentioning

confidence: 99%

Lack of concordance in parapneumonic effusion management in Central European children: Spain is not different

et al. 2016

View full text Add to dashboard Cite

Community acquired pneumonia in children: Treatment of complicated cases and risk patients. Consensus statement by the Spanish Society of Paediatric Infectious Diseases (SEIP) and the Spanish Society of Paediatric Chest Diseases (SENP)

Cited by 9 publications

References 35 publications

Staphylococcus aureus Community-acquired Pneumonia in Children After 13-Valent Pneumococcal Vaccination (2008–2018): Epidemiology, Clinical Characteristics and Outcomes

Staphylococcus aureus Community-acquired Pneumonia in Children After 13-Valent Pneumococcal Vaccination (2008–2018): Epidemiology, Clinical Characteristics and Outcomes

Modern approaches at the management of children with community-acquired pneumonia

Lack of concordance in parapneumonic effusion management in Central European children: Spain is not different

Contact Info

Product

Resources

About